Novartis (NVS) announced new data from TRANSITION study showed Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients.
Entresto has been proven in the landmark PARADIGM-HF study to be superior to
enalapril in reducing CV mortality, HF hospitalization and 30-day hospital
readmission in heart failure patients with reduced ejection fraction.
“We are encouraged by the findings of TRANSITION which show that Entresto, the
new standard of care in heart failure, can be safely initiated in recently
hospitalized patients,” said Shreeram Aradhye, MD, Chief Medical Officer and
Global Head, Medical Affairs, Novartis Pharmaceuticals.
The company noted that 83% of chronic heart failure patients are hospitalized at least once due to an acute heart failure episode. The company added that outlook for patients in first 30 days following hospitalization is poor, with one in four re-admitted during this vulnerable period and up to 10% likely to die.
by RTTNews Staff Writer
Source: Read Full Article